The FDA announced on Jan. 23, 2015, that Mylan Institutional LLC voluntarily recalled Nicardipine Hydrochloride Injection due to subpotency and failed impurity specifications. The recall affects 78,090 vials distributed nationwide.
How to tell if you have it
- Brand: Mylan Institutional
- Product: Nicardipine Hydrochloride Injection, 25 mg/10 ml (2.5 mg/mL), 10 mL single dose vial
- NDC: 67457-224-10
- Lot codes: UW301, UW302 (Exp 02/15); UW303, UW304, UW305, UW306 (Exp 04/15)
- Quantity: 78,090 vials
- Distribution: Nationwide
The hazard
The product is classified as a subpotent drug and failed impurities/degradation specifications. The FDA classified the recall as Class III.
Context
GovInfoNow's records show Mylan Institutional LLC has had 10 other recalls since Feb. 11, 2015. Recent labeling issues include a May 3, 2021 recall for incorrect lot/exp dates on Thiamine HCl Injection and an Aug. 17, 2020 recall involving label mix-ups with Amiodarone Injection. Other recent recalls of similar products include Mylan Prasugrel Tablets Recall (Aug. 17, 2026), Mylan Mycophenolate Mofetil Injection Recall (July 2, 2026), and Mylan Recalls Amnesteem Isotretinoin Capsules Due to Dissolution Failure (Feb. 24, 2026).